Dr. Pratima Chalasani, MD

Dr. Chalasani practices at Carle Foundation Hospital in Urbana, Illinois, part of The Carle Foundation.

Dr. Chalasani's NPI, 1477782522, was assigned on July 10, 2009. Dr. Chalasani holds Illinois license 036130709.

Dr. Chalasani's primary practice is Carle Foundation Hospital, at 611 West Park Street, Urbana, IL 61801 in Champaign County. The practice phone is (217) 383-3311.

Dr. Chalasani's primary practice is Carle Foundation Hospital in Urbana, Illinois, part of The Carle Foundation. Dr. Chalasani is also affiliated with Sarah Bush Lincoln Health Center. The medical group on file is Carle Physician Group. Dmand AI also links Dr. Chalasani to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chalasani practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Chalasani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Chalasani is licensed in Illinois.

CMS data shows 586 Medicare services from Dr. Chalasani across 9 procedure codes in 2024, for 247 Medicare patients. Medicare paid $42,086 for them.

CMS counts 247 Medicare patients who saw Dr. Chalasani in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chalasani's median patient age at 73, with 79% women.

In 2024, Dr. Chalasani wrote 1,065 Medicare Part D claims for 218 patients. 80% of them were for generic drugs. CMS names the drug for 925 of them, across 26 drugs with 11 or more claims each, at $1,473,337 in total drug cost. In 2023, CMS named 817 claims across 23 drugs.

Dr. Chalasani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chalasani as offering telehealth.

Dmand AI links 1 paper to Dr. Chalasani in 2013. Dr. Chalasani's most frequent co-authors are Cathy L. Clausen, MD, Muthuswamy Dhiwakar, MD and Sini Joseph Kalapurakal, MD.

Dmand AI links Dr. Chalasani to 10 clinical trials, 6 of them phase 2 studies. 10 are still active or recruiting. Conditions studied include Carcinosarcoma, Brain Neoplasms and Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 14 general payments to Dr. Chalasani from 9 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 69% of the total. AstraZeneca Pharmaceuticals LP paid the most, $106.